← Leaderboards
Michael Daniel Keller
Children'S Research Institute
$5,524,657
Attributed
$5,524,657
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,524,657 · 4
By mechanism
R01$3,590,968 · 1
R33$1,140,909 · 1
K23$614,280 · 1
R03$178,500 · 1
Top collaborators
No co-investigators on record.
Most similar at Children'S Research Institute
Same institution · by research overlap
- Adeline Lucie Vanderver$19,932,242
- Yi-Wen Chen$5,035,323
- Kanneboyina Nagaraju$4,117,501
- Catherine Mary Bollard$14,999,215
- Daniel J Merenstein$17,048,763
Others in their field
Other Emerging Leaders on “Hematopoietic Stem Cell Transplantation”
- Bronwen Shaw · Medical College Of Wisconsin$24,584,971
- Geoffrey Roger Hill · Fred Hutchinson Cancer Center$8,282,992
- Sumithira Vasu · Ohio State University$5,348,814
- Anthony Sung · Duke University$5,330,635
- Pietro Genovese · Dana-Farber Cancer Inst$4,879,104
- Areej El-Jawahri · Massachusetts General Hospital$4,675,514
Research focus
Hematopoietic Stem Cell TransplantationInfusion ProceduresVirus DiseasesCytomegalovirusFlow CytometryAdenovirusesImmunityVirusSafetyHuman Herpesvirus 4T-LymphocyteViralCellsIn VivoT Cell TherapyResponseAdoptive TransferImmunologic Deficiency SyndromesImmuneCongenital ImmunodeficiencyInterferon Type IiChronicEpitopesFuture
Grant awards (13)
Enhancing efficacy of virus-specific T cell therapy following hematopoietic stem cell transplantation by CD52 knockout$579,879
R33 · FY2025 · HL · contact PI
Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment Following Hematopoietic Stem Cell Transplantation$701,425
R01 · FY2024 · HL · contact PI
Enhancing efficacy of virus-specific T cell therapy following hematopoietic stem cell transplantation by CD52 knockout$561,030
R33 · FY2024 · HL · contact PI
Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment Following Hematopoietic Stem Cell Transplantation$715,637
R01 · FY2023 · HL · contact PI
Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment Following Hematopoietic Stem Cell Transplantation$715,637
R01 · FY2022 · HL · contact PI
Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment Following Hematopoietic Stem Cell Transplantation$722,458
R01 · FY2021 · HL · contact PI
Characterization of the T-cell Response to Human Norovirus Infection$89,250
R03 · FY2021 · AI · contact PI
Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment Following Hematopoietic Stem Cell Transplantation$735,811
R01 · FY2020 · HL · contact PI
Characterization of the T-cell Response to Human Norovirus Infection$89,250
R03 · FY2020 · AI · contact PI
Adoptive Immunotherapy for the Treatment of Viral Infections in Primary Immunodeficiency Disorders$159,760
K23 · FY2019 · HL · contact PI
Adoptive Immunotherapy for the Treatment of Viral Infections in Primary Immunodeficiency Disorders$135,000
K23 · FY2019 · HL · contact PI
Adoptive Immunotherapy for the Treatment of Viral Infections in Primary Immunodeficiency Disorders$159,760
K23 · FY2018 · HL · contact PI
Adoptive Immunotherapy for the Treatment of Viral Infections in Primary Immunodeficiency Disorders$159,760
K23 · FY2017 · HL · contact PI